SPY757.04−0.36%QQQ685.21−0.75%BTC/USD73,342.97−0.79%DIA525.02+0.11%GLD362.14−0.83%TLT80.99+0.09%

Alnylam Pharmaceuticals Inc

ALNYNASDAQ

Trade with Public

$159.85

8.215.41%

Last update: Nov 11, 7:29 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Alnylam Pharmaceuticals (ALNY) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Alnylam Pharmaceuticals (ALNY) stock.

Analyst Consensus — 23 Analysts

21Buy

2Hold

# Analysts23

Latest Upgrades and Downgrades for Alnylam Pharmaceuticals Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Barclays	Eliana Merle	PT Cut	Overweight	$450→$380
—	Truist Securities	Danielle Brill	Downgrade	Buy→Hold	$315→$225
—	Canaccord Genuity	Whitney Ijem	PT Cut	Buy	$429→$323
—	UBS	Joon Lee	PT Cut	Buy	$354→$329
—	TD Cowen	Ritu Baral	PT Cut	Buy	$482→$354
—	Bernstein	Zhiqiang Shu	Downgrade	Outperform→Market Perform	$376→$199
—	Morgan Stanley	Michael Ulz	PT Cut	Equal-Weight	$300→$240
—	Goldman Sachs	Salveen Richter	PT Cut	Buy	$536→$320
—	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$253→$220
—	RBC Capital	Luca Issi	PT Cut	Outperform	$345→$280
—	Raymond James	Martin Auster	Downgrade	Strong Buy→Outperform	$420→$315
—	Needham	Joseph Stringer	PT Cut	Buy	$357→$243
—	UBS	Joon Lee	Assumes	Buy	$550→$354
—	Citigroup	Eric Joseph	PT Cut	Buy	$340→$320
—	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$256→$253
—	RBC Capital	Luca Issi	PT Cut	Outperform	$350→$345
—	JP Morgan	Jessica Fye	PT Cut	Overweight	$375→$369
—	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$455
—	Jefferies	Faisal Khurshid	PT Raise	Hold	$230→$260
—	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$455

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals (ALNY) Stock Price Target 2026

Latest Upgrades and Downgrades for Alnylam Pharmaceuticals Stock

Alnylam Pharmaceuticals (ALNY) Stock Price Target 2026

Latest Upgrades and Downgrades for Alnylam Pharmaceuticals Stock

Analyst Ratings News

PRO
Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $380

PRO
Truist Securities Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $225

PRO
Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $323

5 Stock Picks Last Month From Wall Street's Most Accurate Analysts

PRO
TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $354

PRO
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $240

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $380

PRO
Truist Securities Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $225

PRO
Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $323

5 Stock Picks Last Month From Wall Street's Most Accurate Analysts

PRO
TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $354

PRO
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $240

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals (ALNY) Stock Price Target 2026

Latest Upgrades and Downgrades for Alnylam Pharmaceuticals Stock

Alnylam Pharmaceuticals (ALNY) Stock Price Target 2026

Latest Upgrades and Downgrades for Alnylam Pharmaceuticals Stock

Analyst Ratings News

PROBarclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $380

PROTruist Securities Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $225

PROCanaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $323

5 Stock Picks Last Month From Wall Street's Most Accurate Analysts

PROTD Cowen Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $354

PROMorgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $240

People Also Watch

People Also Watch

Analyst Ratings News

PROBarclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $380

PROTruist Securities Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $225

PROCanaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $323

5 Stock Picks Last Month From Wall Street's Most Accurate Analysts

PROTD Cowen Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $354

PROMorgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $240

PRO
Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $380

PRO
Truist Securities Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $225

PRO
Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $323

PRO
TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $354

PRO
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $240

PRO
Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $380

PRO
Truist Securities Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $225

PRO
Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $323

PRO
TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $354

PRO
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $240